AtriCure Announces Pricing of Public Offering of Common Stock
October 04 2018 - 6:09PM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments
for atrial fibrillation (Afib) and left atrial appendage (LAA)
management, today announced the pricing of its underwritten
offering of 2.5 million shares of its common stock at a price to
the public of $30.75 per share pursuant to its existing shelf
registration statement. Net proceeds to AtriCure from the offering
are expected to be approximately $72 million, after deducting
underwriting discounts and commissions and estimated offering
expenses. AtriCure has granted to the underwriters of the offering
a 30-day option to purchase up to an additional 375,000 shares of
common stock on the same terms and conditions. The offering is
expected to close on October 10, 2018, subject to customary closing
conditions. AtriCure intends to use the net proceeds from the
offering for working capital and other general corporate purposes,
which may include repayment of debt, the possible pursuit of
strategic acquisitions, and other potential corporate or market
development activities.
J.P. Morgan and Piper Jaffray & Co. are acting as joint
book-running managers for the offering. Canaccord Genuity LLC,
Leerink Partners, and Stifel, Nicolaus & Company, Incorporated
are acting as co-managers.
A shelf registration statement on Form S-3 relating to the
common stock offered in the underwritten offering described above
was declared effective by the Securities and Exchange Commission
(SEC) on June 24, 2016. The offering is being made only by means of
a written prospectus and prospectus supplement that form a part of
the registration statement. A preliminary prospectus supplement has
been filed with the SEC and is available on the SEC’s website
at www.sec.gov. A final prospectus supplement will be filed
with the SEC. Copies of the preliminary prospectus supplement and
accompanying prospectus, and when available, copies of the final
prospectus supplement and the accompanying prospectus, may also be
obtained by contacting J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, or by phone at
1-866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; or
Piper Jaffray & Co., Attention: Prospectus Department, 800
Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at
800-747-3924, or by email at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About AtriCureAtriCure,
Inc. provides innovative technologies for the treatment of Afib and
related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around
the globe use AtriCure technologies for the treatment of Afib and
reduction of Afib related complications. AtriCure’s Isolator®
Synergy™ Ablation System is the first and only medical device to
receive FDA approval for the treatment of persistent Afib.
AtriCure’s AtriClip Left Atrial Appendage Exclusion System products
are the most widely sold LAA management devices worldwide, with
more than 150,000 implanted to date.
Forward-Looking
StatementsThis announcement contains forward-looking
statements, including statements relating to AtriCure’s
expectations regarding the completion, timing and size of the
proposed public offering and use of proceeds. These statements are
subject to significant risks and uncertainties; actual results
could differ materially from those projected and AtriCure cautions
investors not to place undue reliance on the forward-looking
statements contained in this release. These risks and uncertainties
include, without limitation, risks and uncertainties related to
market conditions and satisfaction of customary closing conditions
related to the public offering. There can be no assurance that
AtriCure will be able to complete the public offering on the
anticipated terms, or at all. Risks and uncertainties relating to
AtriCure and its business can be found in AtriCure’s Annual Report
on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC
which contain risk factors. Risk factors are also contained in the
preliminary prospectus supplement filed with the SEC with respect
to the offering on October 3, 2018 and will be contained in the
final prospectus supplement to be filed with the SEC with respect
to the offering. AtriCure undertakes no duty or obligation to
update any forward-looking statements contained in this release as
a result of new information, future events, changes in AtriCure’s
expectations or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181004005859/en/
AtriCure, Inc.Andy Wade, 513-755-4564Senior Vice President and
Chief Financial Officerawade@atricure.comorGilmartin GroupLynn
Pieper Lewis, 415-937-5402Investor
Relationslynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2023 to Apr 2024